Goldman Sachs-backed Attovia eyes US$731.5 million valuation in upsized U.S. IPO

Biopharmaceutical company Attovia Therapeutics said on Tuesday it was targeting a valuation of US$731.5 million in its upsized initial public offering, signaling strong demand for biopharma listings.